NFKB1 and COVID-19: Moreover, a previous study concluded that SARS-CoV-2 suppresses PPAR expression in the lungs and abrogates one of the main anti-inflammatory cores for NF-κB activity, thereby exerting a hyperinflammatory response in patients with severe COVID-19 (152).